285 related articles for article (PubMed ID: 28741453)
1. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Huang F; Ajavon A; Huang E; Lettieri J; Liu R; Peña C; Berse M
Thyroid; 2017 Sep; 27(9):1118-1127. PubMed ID: 28741453
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
[TBL] [Abstract][Full Text] [Related]
3. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.
Wang X; Zhang X; Liu F; Wang M; Qin S
Pharm Biol; 2017 Dec; 55(1):1863-1867. PubMed ID: 28614959
[TBL] [Abstract][Full Text] [Related]
4. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
[TBL] [Abstract][Full Text] [Related]
8. Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
Bellesoeur A; Carton E; Mir O; Groussin L; Blanchet B; Billemont B; Clerc J; Goldwasser F
Invest New Drugs; 2014 Jun; 32(3):569-72. PubMed ID: 24399106
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
10. In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
Mai H; Huang J; Zhang Y; Qu N; Qu H; Mei GH; Liu J; Xu X; Chen L
Oncotarget; 2017 Jun; 8(26):43458-43469. PubMed ID: 28404979
[TBL] [Abstract][Full Text] [Related]
11. Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
Shimada M; Okawa H; Kondo Y; Maejima T; Kataoka Y; Hisamichi K; Maekawa M; Matsuura M; Jin Y; Mori M; Suzuki H; Shimosegawa T; Mano N
Tohoku J Exp Med; 2015 Nov; 237(3):173-82. PubMed ID: 26477611
[TBL] [Abstract][Full Text] [Related]
12. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
13. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
14. Daily Administration of Short-Acting Liothyronine Is Associated with Significant Triiodothyronine Excursions and Fails to Alter Thyroid-Responsive Parameters.
Jonklaas J; Burman KD
Thyroid; 2016 Jun; 26(6):770-8. PubMed ID: 27030088
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
17. Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
Fucile C; Marenco S; Bazzica M; Zuccoli ML; Lantieri F; Robbiano L; Marini V; Di Gion P; Pieri G; Stura P; Martelli A; Savarino V; Mattioli F; Picciotto A
Med Oncol; 2015 Jan; 32(1):335. PubMed ID: 25429830
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib therapy decreases the clearance of thyrotropin.
Verloop H; Smit JW; Dekkers OM
Eur J Endocrinol; 2013 Feb; 168(2):163-7. PubMed ID: 23125304
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Noda S; Shioya M; Hira D; Fujiyama Y; Morita SY; Terada T
Cancer Chemother Pharmacol; 2013 Jul; 72(1):269-72. PubMed ID: 23673446
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination.
Abdulrahman RM; Verloop H; Hoftijzer H; Verburg E; Hovens GC; Corssmit EP; Reiners C; Gelderblom H; Pereira AM; Kapiteijn E; Romijn JA; Visser TJ; Smit JW
J Clin Endocrinol Metab; 2010 Aug; 95(8):3758-62. PubMed ID: 20484486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
